Ciclesonide Market Report - Forecast (2022-2027)
The Ciclesonide Market size is estimated to reach?$671.7 million?by 2027, growing at a?CAGR of 2.1%?during the forecast period 2022-2027. Ciclesonide is a glucocorticoid utilized to treat obstructive airway ailments, asthma and?allergic rhinitis. Ciclesonide brand names include Alvesco for asthma and Omnaris, Omniair, Zetonna and Alvesco for hay fever in the U.S. and Canada. Ciclesonide price is about $296 for Alvesco inhalation aerosol (CFC free 80 mcg/inh) for a supply of 6.1 grams. Considering the ciclesonide mechanism of action, the body transforms ciclesonide to des ciclesonide, which is the active kind of medication. The Ciclesonide market in the U.S is being fuelled by the increasing predominance of asthma and allergy rhinitis. Ciclesonide side effects include a hoarse voice, sore throat and oral. The increasing pollution across the world resulting in asthma symptoms is set to drive the Ciclesonide Market. The surging application of medication with the ciclesonide brand name as a preventer for asthma is set to propel the growth of the Ciclesonide Industry during the forecast period 2022-2027. This represents the Ciclesonide Industry Outlook.
Ciclesonide Market Report Coverage
The?“Ciclesonide Market Report - Forecast (2022-2027)”?by IndustryARC, covers an in-depth analysis of the following segments in the Ciclesonide Market.
By Indication:?Asthma and Allergic Rhinitis.
By End-user:?Adults and Children.
By Geography:?North America (the U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest Of The World (the Middle East and Africa).
Key Takeaways
Ciclesonide Market: Market Share (%) by Region, 2021
For More Details on This Report -?Request for Sample
Ciclesonide Market Segment Analysis - by Indication
The Ciclesonide Market based on indication can be further segmented into Asthma and Allergic Rhinitis. The Asthma Segment held the largest Ciclesonide market share in 2021. This growth is owing to the rising pervasiveness of asthma most likely ascribed to genetic or environmental factors. In people with asthma, the ciclesonide mechanism of action involves the elimination of inflammation within the airways. The expanding application of ciclesonide to avert and decrease the symptoms of asthma is further propelling the growth of the Asthma segment.
Furthermore, the Allergic Rhinitis segment is estimated to grow with the fastest?CAGR of 3.0%?during the forecast period 2022-2027 owing to the increasing predominance of allergic rhinitis attributed to the overreaction of the immune system to some substances termed allergens which could be outdoor or indoor allergens, irritants like cigarette smoke or concealed food allergens.
Ciclesonide Market Segment Analysis - by End-user
The Ciclesonide Market based on end-user can be further segmented into Adults and Children. The Adults Segment held the largest Ciclesonide market share in 2021. This growth is owing to the surging application of ciclesonide to avert asthma attacks in mature grown-ups. Ciclesonide is a novel steroid that is recorded to prepare lower active steroids until the medication arrives at the lung on inhalation leading to decreased possibility of throat symptoms. The heightening application of ciclesonide nasal spray for the treatment of allergic rhinitis is further propelling the growth of this segment. Furthermore, the Children segment is estimated to grow with the fastest?CAGR of 3.1%?during the forecast period 2022-2027 owing to the safe and effective application of ciclesonide nasal spray for children with perennial allergic rhinitis and to avert asthma attacks in children aged at least 12 years.
Ciclesonide Market Segment Analysis - by Geography
The Ciclesonide Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Ciclesonide Market) held the largest Ciclesonide market share with 35% of the overall market in 2021. The growth of this region is owing to the increasing predominance of asthma and allergy rhinitis in the North American region. The surging medication launches are further propelling the growth of the Ciclesonide Industry, thereby contributing to the Ciclesonide Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the extensive application of ciclesonide to handle symptoms of long-term allergies and asthma in the Asia-Pacific region. The enormous patient pool is further fuelling the progress of the Ciclesonide Market in the Asia-Pacific region.
Ciclesonide Market Drivers
Surging Investigations on Ciclesonide are Projected to Drive the Growth of the Ciclesonide Market:
Ciclesonide is undergoing phase III investigations in the U.S. It is thought of as a third-generation inhaled glucocorticoid owing to the numerous rare features that differentiate it from additional members of the class. As it is present in the canister, ciclesonide is in an inactive form. Once it arrives in the lung, it is metabolized by lung esterases to its active form, des ciclesonide. Des ciclesonide has great glucocorticoid receptor binding affinity and is inclined to exhibit important anti-inflammatory impacts. Des ciclesonide is 99% protein bound. The surging investigations on ciclesonide are therefore fuelling the growth of the Ciclesonide Market during the forecast period 2022-2027.
领英推荐
Soaring Significance of Ciclesonide Brand Names is Expected to Boost the Growth of the Ciclesonide Industry:
The products accessible in the U.S. that include ciclesonide and contribute to the growth of the ciclesonide market in the U.S. involve Ciclesonide brand names termed Alvesco, Omnaris and Zetonna. Alvesco includes ciclesonide systemic belonging to the drug class of inhaled corticosteroids. Ciclesonide systemic is applied in the treatment of asthma and in asthma maintenance. Ciclesonide nasal is marketed under ciclesonide brand names termed Omnaris and Zetonna. It belongs to the drug class of nasal steroids and is utilized in the treatment of Allergic Rhinitis. Considering the ciclesonide price, the price for Omnaris nasal spray (50 mcg/inh) is about $320 for a supply of 12.5 grams, relying on the pharmacy one visit. The soaring significance of ciclesonide brand names is driving the growth of the Ciclesonide Industry, thereby contributing to the Ciclesonide Industry Outlook during the forecast period 2022-2027.
Ciclesonide Market Challenges
Limitations of Ciclesonide are Hampering the Growth of the Ciclesonide Market:
The ciclesonide mechanism of action involves the body transforming ciclesonide to des-ciclesonide, which is the active form of the medication. Glucocorticoid steroids have powerful anti-inflammatory activities. “The percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged 99% each, with 1% of unbound drug detected in the systemic circulation”. Ciclesonide inhalation will not perform sufficiently fast to treat an asthma attack. A fast-acting inhalation medication needs to be utilized for an asthma attack. Ciclesonide side effects on inhalation include hives, hardship in breathing and swelling of the face, lips, tongue or throat. These issues are thus hampering the growth of the Ciclesonide Market.
Ciclesonide Industry Outlook
Novel product launches, strategic mergers and acquisitions, strategic alliances and R&D activities are key strategies players in the Ciclesonide Market adopt. The top 10 companies in the Ciclesonide Market are:
Recent Developments
Relevant Reports:
Report Code: HCR 0876
Report Code: HCR 84738
Report Code: HCR 41227
For more Lifesciences and Healthcare Market reports, please?click here